{"id":"W2606639948","doi":"10.5489/cuaj.4398","title":"First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience","year":2017,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre; Montreal General Hospital; BC Cancer Agency; University of Calgary; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Ottawa Hospital; CancerCare Manitoba; University Health Network; University of Toronto; University of Alberta; Queen Elizabeth II Health Sciences Centre; McGill University","funders":"","keywords":"Pazopanib; Sunitinib; Medicine; Hazard ratio; Renal cell carcinoma; Internal medicine; Oncology; Proportional hazards model; Confidence interval; Mucositis; Kidney cancer; Urology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009824865,0.0002279639,0.000379218,0.0002658966,0.001845187,0.0003810806,0.0004630213,0.0001938953,0.001267774],"category_scores_gemma":[0.001768563,0.0001371702,0.0001510295,0.000171716,0.0001243498,0.0001620086,0.00003020534,0.000923758,0.00008496576],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003989333,"about_ca_system_score_gemma":0.002906082,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.4444843,"about_ca_topic_score_gemma":0.9293401,"domain_scores_codex":[0.9976079,0.0002262964,0.0004731146,0.0002757696,0.0004910851,0.0009258683],"domain_scores_gemma":[0.9970698,0.0002527607,0.0004206511,0.0004159003,0.0002645207,0.001576386],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000116895,0.00006335812,0.9897432,0.000007539927,0.00004501569,0.005150259,0.0008760517,0.00008467422,0.00003547174,0.00009389189,0.002905623,0.0008780178],"study_design_scores_gemma":[0.001733641,0.0004520944,0.9667368,0.00001619579,0.00009311624,0.0006473492,0.0002443947,0.0002291647,0.0001203443,0.0002419865,0.0293236,0.0001612941],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9458846,0.000218899,0.00000614175,0.04575934,0.0002650065,0.0003818109,0.00004160655,0.000008431386,0.007434107],"genre_scores_gemma":[0.9939374,0.00004455309,0.0001390343,0.003465099,0.0003352197,0.00003859173,0.0000171016,0.00001855641,0.002004474],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4848558,"threshold_uncertainty_score":0.9998342,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05555852489601952,"score_gpt":0.276163788417907,"score_spread":0.2206052635218875,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}